CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Anti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC Cohort.
Authors
Eva Ardanaz
Dagfinn Aune
+38 more
Heiner Boeing
Marie-Christine Boutron-Ruault
Jenny Brändstedt
Maria-Dolores Chirlaque
Daniel W Cramer
Miren Dorronsoro
Laure Dossus
Eric J Duell
Raina N Fichorova
Renée T Fortner
Inger T Gram
Marc Gunter
Louise Hansen
Annika Idahl
Theron Johnson
Rudolf Kaaks
Kay-Tee Khaw
Vittorio Krogh
Marina Kvaskoff
Amalia Mattiello
Giuseppe Matullo
Melissa A Merritt
Björn Nodin
N Charlotte Onland-Moret
Philippos Orfanos
Domenico Palli
Eleni Peppa
J Ramón Quirós
Gianluca Severi
Maria-Jose Sánchez-Perez
Kathryn L Terry
Anne Tjønneland
Ruth C Travis
Antonia Trichopoulou
Rosario Tumino
Allison F Vitonis
Elisabete Weiderpass
Hidemi Yamamoto
Publication date
16 April 2018
Publisher
Cancer Epidemiol Biomarkers Prev
Doi
Cite
Abstract
Background: Neoplastic and non-neoplastic events may raise levels of mucins, CA15.3, and CA125, and generate antibodies against them, but their impact on epithelial ovarian cancer (EOC) risk has not been fully defined.Methods: CA15.3, CA125, and IgG1 antibodies against them were measured in 806 women who developed EOC and 1,927 matched controls from the European Prospective Investigation of Nutrition and Cancer. Associations between epidemiologic factors and anti-mucin antibodies were evaluated using generalized linear models; EOC risks associated with anti-mucin antibodies, by themselves or in combination with respective antigens, were evaluated using conditional logistic regression.Results: In controls, lower antibodies against both mucins were associated with current smoking; and, in postmenopausal women, higher levels with longer oral contraceptive use and later-age-at and shorter-interval-since last birth. Lower anti-CA15.3 antibodies were associated with higher body mass and, in premenopausal women, more ovulatory cycles. Higher anti-CA15.3 and anti-CA125 antibodies were associated with higher risk for mucinous EOC occurring ≥ 3 years from enrollment. Long-term risk for serous EOC was reduced in women with low CA125 and high anti-CA125 antibodies relative to women with low concentrations of both.Conclusions: We found general support for the hypothesis that anti-mucin antibody levels correlate with risk factors for EOC. Antibodies alone or in combinations with their antigen may predict longer term risk of specific EOC types.Impact: Anti-CA125 and anti-CA15.3 antibodies alone or in perspective of antigens may be informative in the pathogenesis of EOC subtypes, but less useful for informing risk for all EOC. Cancer Epidemiol Biomarkers Prev; 27(7); 790-804. ©2018 AACR.The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM; France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund, Statistics Netherlands (The Netherlands); ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford; United Kingdom
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Fondo Bibliográfico Digital Institucional
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:www.repositoriosalud.es:10...
Last time updated on 17/02/2023
Sustaining member
Apollo (Cambridge)
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:www.repository.cam.ac.uk:1...
Last time updated on 08/02/2019
Utrecht University Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:dspace.library.uu.nl:1874/...
Last time updated on 14/02/2019
Lund University Publications
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:lup.lub.lu.se:6627370c-299...
Last time updated on 03/08/2018
NARCIS
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 15/05/2019